MDACC Study No:2010-0933 ( NCT No: NCT01260545)
Title:Phase I Study of CA-18C3 in Subjects with Advanced Hematologic Malignancies
Principal Investigator:Gautam Borthakur
Treatment Agent:CA-18C3
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of CA-18C3 that can be given to patients with advanced blood cancers.
Researchers also want to learn how much and for how long the study drug stays
in your body after it has been given to you. The safety of this drug will also
be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:CA-18C3
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:XBiotech USA, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults